Morning Briefing
Summaries of health policy coverage from major news organizations
Minorities Are Underrepresented In Staph Antibiotic Trials: Study
A systematic review of randomized controlled trials (RCTs) on antibiotics for Staphylococcus aureus infections found widespread underrepresentation of racial and ethnic minorities, researchers reported late last week in Clinical Infectious Diseases. (Dall, 2/6)
Chinese researchers yesterday reported promising results in a phase 2 trial of a novel antiviral called onradivir for treating seasonal flu. (Schnirring, 2/6)
A malaria vaccine developed by the University of Oxford and the Serum Institute of India prevented around three-quarters of symptomatic malaria cases in young children the first year after they got the shots, results from a large trial showed on Thursday. The vaccine, which has already been approved for use by regulators in three West African countries and the World Health Organization, is the second to become available this year. (Rigby, 2/1)
Results of a phase 3 trial in the聽New England Journal of Medicine聽(NEJM) show 80% protection for the single-dose tetravalent (four-strain)聽Butantan-Dengue Vaccine (Butantan D-V) among participants with no evidence of previous dengue exposure and 89% protection in those with a history of exposure. (Soucheray, 2/2)
French vaccine maker Valneva said on Monday it had sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million. Valneva was awarded a tropical disease PRV in November 2023 after it developed Ixchiq, its single-dose vaccine for the prevention of the disease caused by the chikungunya virus, the company said. Ixchiq was the first preventive shot to be approved in the United States for the mosquito-borne disease. (2/5)
Get Free Report posted better-than-expected fourth-quarter earnings Tuesday, while issuing a robust near-term outlook, thanks in part to surging sales of its diabetes and weight-loss treatments, which continue to offset a slump in revenue for its legacy diabetes drug Trulicity. (Baccardax, 2/6)
AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous prediction. The Chicago-based drugmaker has been counting on revenues from its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira. (Leo and Wingrove, 2/2)
